Effects of short-term growth hormone therapy in short children without growth hormone deficiency. 1990

K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
Department of Medicine, Tokyo Women's Medical College, Japan.

Evaluation of 24-hour endogenous growth hormone (GH) secretion was carried out in 62 children, aged 7-16 years, who did not have classic GH deficiency (GHD). The mean 24-hour GH concentration, determined at 20-minute intervals over 24 hours, was variable, ranging from 1.28 to 11.39 micrograms/l with a mean of 4.95 +/- 2.55 micrograms/l (+/- SD). There was a positive correlation between mean 24-hour GH concentration and plasma insulin-like growth factor I (IGF-I) values (r = 0.54; p less than 0.01). Recombinant human GH, 0.1 IU/kg/day was administered to 30 of the 62 children for 6 months followed by 6 months' observation without treatment. Thereafter, GH was administered at the same dose for a further 6 months to 16 children. The mean height velocities before, during, and after the first treatment period were 4.3 +/- 0.9, 7.3 +/- 1.9 and 4.9 +/- 2.0 cm/year (mean +/- SD), respectively. The height velocity during treatment was greater than pre- and post-treatment values (p less than 0.001). The height velocity increased again during the second treatment period to a mean of 8.5 +/- 2.0 cm/year (p less than 0.001). Nine other children were treated continuously in a similar manner for 1 year and their height velocity increased significantly from 4.1 +/- 1.4 to 6.0 +/- 1.9 cm/year (p less than 0.001). According to our criteria, 29 of the 39 children (74.4%) who were treated for 6-12 months showed a GH-dependent height increase during therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D001827 Body Height The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. Body Heights,Height, Body,Heights, Body
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006128 Growth Gradual increase in the number, the size, and the complexity of cells of an individual. Growth generally results in increase in ORGAN WEIGHT; BODY WEIGHT; and BODY HEIGHT.
D006130 Growth Disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. Included here are both acceleration and retardation of growth. Stunted Growth,Stunting,Disorder, Growth,Growth Disorder,Growth, Stunted,Stuntings

Related Publications

K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
July 1992, Nutrition reviews,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
January 1989, Journal of endocrinological investigation,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
July 1996, Hormone research,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
November 2010, The Journal of the Association of Physicians of India,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
April 1984, The New England journal of medicine,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
June 1996, Fortschritte der Medizin,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
July 1991, The Journal of pediatrics,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
January 1990, Acta paediatrica Scandinavica. Supplement,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
January 1970, The Journal of clinical endocrinology and metabolism,
K Takano, and N Hizuka, and K Asakawa, and I Sukegawa, and R Horikawa, and K Shizume
February 1984, The Journal of pediatrics,
Copied contents to your clipboard!